However, within this NSAID class, there are differences as to risk for heart disease. As noted in a nice review published in PLoS Medicine , the authors noted that rofecoxib, diclofenac & etoricoxib rank highest risk for heart disease compared to non-use while naproxen is ranked as low risk. Despite this widespread knowledge, diclofenac & etoricoxib accounted for one of every three NSAID pills sold in 15 countries worldwide regardless of income level. In fact, higher risk diclofenac was considered an essential medication by 74 countries while lower risk naproxen was considered essential in only 27 countries.
In other words, government officials in charge of policy are ignoring evidence-based medicine. Luckily for you & me, we have a choice here in the States. We have ready access to lower risk naproxen (while higher risk diclofenac is still available to those few individuals who don't respond to any other NSAID).